Standard- vs. low-dose rivaroxaban in patients with atrial fibrillation: a systematic review and meta-analysis.

Guangyan MuHanxu ZhangZhiyan LiuQiufen XieShuang ZhouZining WangZhe WangKun HuJingyi HouNan ZhaoQian XiangYi Min Cui

Published in: European journal of clinical pharmacology (2021)

In Caucasians with AF, standard-dose rivaroxaban may prevent MACE significantly better than low-dose treatment. Further studies in Asians are needed to verify the advantages of the standard dose.

Keyphrases

low dose
atrial fibrillation
venous thromboembolism
high dose
pulmonary embolism
smoking cessation